Abstract Number: 1905 • 2015 ACR/ARHP Annual Meeting
Stimulators of Soluble Guanylate Cyclase (sGC) Inhibit Experimental Skin Fibrosis of Different Aetiologies
Background/Purpose: Systemic sclerosis (SSc) is characterised by fibrosis and vascular alterations, both of which account for the high morbidity and mortality of SSc. Although several…Abstract Number: 1906 • 2015 ACR/ARHP Annual Meeting
Stimulators of Soluble Guanylate Cyclase (sGC) Improve Wound Healing in the Tsk-1 Mouse Skin Fibrosis Mode
Background/Purpose: Systemic sclerosis (SSc) is a multisystem disorder characterized by thickening of the skin and distinctive involvement of multiple internal organs. In addition to skin…Abstract Number: 1907 • 2015 ACR/ARHP Annual Meeting
Inhibition of Phosphodiesterase 4 (PDE4) Reduces Dermal Fibrosis By Interfering with the Release of Pro-Fibrotic Cytokines from M2-Macrophages
Background/Purpose: PDE4 catalyses the breakdown of the second messengers cAMP and cGMP to modulate intracellular effects. PDE4 is mainly expressed in inflammatory cells, and its…Abstract Number: 1908 • 2015 ACR/ARHP Annual Meeting
Macitentan Responsiveness Supports the Validity of a Murine Model of Pulmonary Hypertension in Scleroderma Associated with Altered Tgfbeta/BMPR2 Signalling
Background/Purpose: Pulmonary arterial hypertension (PAH) is an important complication of systemic sclerosis (SSc) that occurs in around 10% of cases. We have previously shown that…Abstract Number: 1909 • 2015 ACR/ARHP Annual Meeting
Nailfold Capillaroscopic Assessment and Vascular Biomarkers in Systemic Sclerosis: Low CD40L Levels in Patients with Late Scleroderma Patterns
Background/Purpose: To determine the relationship between vascular biomarkers reflecting the vascular injury and neoangiogenesis with nailfold capillaroscopic changes in systemic sclerosis (SSc). Methods: Seventy-two SSc…Abstract Number: 1910 • 2015 ACR/ARHP Annual Meeting
Increased Circulating CD204/CD206 Double Positive Monocyte/Macrophages in Systemic Sclerosis Patients with “Early” Capillaroscopic Pattern of Microvascular Damage
Background/Purpose: Immune-inflammatory cells participate together with endothelial cells and myofibroblasts in the tissue damage that characterizes fibrotic diseases, including systemic sclerosis (SSc) (1). Among immune…Abstract Number: 1911 • 2015 ACR/ARHP Annual Meeting
Monocyte Chemoattractant Protein-1 (MCP-1, CCL2) Is a Potential Local Marker of Renal Involvement in Scleroderma
Background/Purpose: Renal disease in scleroderma (SSc), including scleroderma renal crisis (SRC), remains a major clinical challenge. Previous studies showed up to 50% of SSc patients…Abstract Number: 1912 • 2015 ACR/ARHP Annual Meeting
Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Immune Abnormalities in Animal Models of Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by vasculopathy and fibrosis of the skin and various internal organs. Glycyrrhizin, a triterpenoid saponin…Abstract Number: 1913 • 2015 ACR/ARHP Annual Meeting
Lysyl Oxidase Induces Fibrosis Via Upregulation of IL-6 and Serves As a Biomarker to Monitor Response to Therapy
Background/Purpose: Lysyl oxidase (LOX) is a copper-dependent amine oxidase whose primary function is the covalent crosslinking of collagens in the extracellular matrix (ECM). Fibrosis is…Abstract Number: 1914 • 2015 ACR/ARHP Annual Meeting
Oncostatin M As a Potential Molecular Target in Systemic Sclerosis
Background/Purpose: Oncostatin M (OSM) is a pleiotropic member of the gp130/ IL-6 cytokine family, produced by a variety of immune cells, including macrophages, neutrophils…Abstract Number: 1915 • 2015 ACR/ARHP Annual Meeting
Pathogenetic Overlap Between Localised and Systemic Scleroderma: A Study of Nodular and Keloidal Morphea Occurring in Systemic Sclerosis
Background/Purpose: Localised scleroderma can occur in overlap with systemic sclerosis (SSc); nodular and keloidal morphea are rare subtypes but can be disfiguring and challenging to…Abstract Number: 1916 • 2015 ACR/ARHP Annual Meeting
Validation of Novel Biomarker Candidates for Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease that manifests as progressive fibrosis of the skin and internal organs. SSc is associated with the…Abstract Number: 1917 • 2015 ACR/ARHP Annual Meeting
Developing and Validating a Serum Biomarker for the Extent of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: In this study we aimed to both agonistically investigate alterations in the serum proteome of patients with diffuse cutaneous systemic sclerosis (dcSSc), as well…Abstract Number: 1918 • 2015 ACR/ARHP Annual Meeting
Pharmacologic Targeting of Mitochondrial Dysfunction in Systemic Sclerosis: Enhanced SIRT3 Signaling
Background/Purpose: Recent evidences suggest that cytosolic and mitochondrial reactive oxygen species (ROS), play pivotal roles in modulating TGF-β-induced profibrotic responses and are implicated in pathogenesis…Abstract Number: 1919 • 2015 ACR/ARHP Annual Meeting
Genetic Deletion of Toll-like Receptor 4 (Tlr4) Abrogates TGF-β1-Induced Endothelial-to-Mesenchymal Transition (EndoMT) in Murine Pulmonary Endothelial Cells
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease of unknown etiology whose pathogenesis involves the regulation of a diverse range of molecular pathways. The…
ACR Meeting Abstracts